AstraZeneca Leaps Into Nanomedicine With Bind Cancer Deal
This article was originally published in The Pink Sheet Daily
AstraZeneca signs on with Bind to develop a nanotechnology-based, targeted kinase inhibitor that could be used in a number of liquid and solid cancers. For Bind, the news is highly validating as the company’s third deal with a major biopharma in 2013.
You may also be interested in...
Big drugmakers will be watching closely to see if second-generation nanomed companies can program small particles to pack big pharmaceutical effects. We profile four start-ups that hope to show that they can: Blend Biosciences, Kala Pharma, Qualiber Technologies, and Uroboros Technologies.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.